20/20 Biolabs, Inc. (AIDX) stock
AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 6/3059% below fair value
$0.20−0.02 (-9.38%)
Close on Nov 12, 2026Market cap $2.60MP/E –Yield –
20/20 Biolabs EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$0.76.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.76 | – |
| FY2024 | Dec 31, 2024 | -$1.16 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.26 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.28 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.17 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.16 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?